BBP - Currents Of Disruption: Focusing On Fundamentals In Biotech
By Andy Acker, CFA & Daniel Lyons, Ph.D., CFA & John Scotti, D.Phil.
The biotech industry is experiencing a renaissance, with the U.S. approving a record number of novel therapies in 2018. But not all drugs are created equal, say members of the Janus Henderson Global Life Sciences strategy, making it important for investors to focus on both the science and commercial potential of new medicines.
Innovation is a hallmark of biotechnology, and the medical breakthroughs that the industry is now delivering could arguably be called unprecedented. But even as the potential for growth ramps